Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (71-80 of 752) with videos related to

Pageof 76
Sort By:
Heart (British Cardiac Society)|January 12, 2010
Network models for large cities: the European experienceKurt Huber, Patrick Goldstein, Nicolas Danchin, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 19, 2019
Is P2Y12 inhibitor therapy associated with an increased risk of cancer?Christoph C Kaufmann, Alexander R Lyon, Johann Wojta, et al.
International Journal of Emergency Medicine|July 20, 2013
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolismPatrick Goldstein, Ismaïl Elalamy, Kurt Huber, et al.
Frontiers in Psychiatry|April 8, 2024
Risk and protection factors of mental stress among medical staff in the third year of the COVID-19 pandemicChristiane Eichenberg, Raphaela Schneider, Phillip Auvera, et al.
International Journal of Cardiology|June 22, 2015
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpointAndrea Rubboli, Stefan Agewall, Kurt Huber, et al.
European Journal of Internal Medicine|January 15, 2017
New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its doseAndrea Rubboli, Stefan Agewall, Kurt Huber, et al.
Vascular Pharmacology|July 23, 2022
Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapyBenjamin Panzer, Patricia P Wadowski, Kurt Huber, et al.
Wiener Medizinische Wochenschrift (1946)|March 16, 2010
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitusSerdar Farhan, Thomas Höchtl, Alexandra Kautzky-Willer, et al.
Journal of Hypertension|May 3, 2016
Awareness, treatment, and control of hypertension in Austria: a multicentre cross-sectional studyMiklos Rohla, Heinz Haberfeld, Maximilian Tscharre, et al.
European Heart Journal|August 24, 2018
Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)Gregory Y H Lip, Jean-Philippe Collet, Michael Haude, et al.
Pageof 76

Showing results (71-80 of 752) with videos related to

Sort By:
Pageof 76
Heart (British Cardiac Society)|January 12, 2010
Network models for large cities: the European experienceKurt Huber, Patrick Goldstein, Nicolas Danchin, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 19, 2019
Is P2Y12 inhibitor therapy associated with an increased risk of cancer?Christoph C Kaufmann, Alexander R Lyon, Johann Wojta, et al.
International Journal of Emergency Medicine|July 20, 2013
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolismPatrick Goldstein, Ismaïl Elalamy, Kurt Huber, et al.
Frontiers in Psychiatry|April 8, 2024
Risk and protection factors of mental stress among medical staff in the third year of the COVID-19 pandemicChristiane Eichenberg, Raphaela Schneider, Phillip Auvera, et al.
International Journal of Cardiology|June 22, 2015
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpointAndrea Rubboli, Stefan Agewall, Kurt Huber, et al.
European Journal of Internal Medicine|January 15, 2017
New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its doseAndrea Rubboli, Stefan Agewall, Kurt Huber, et al.
Vascular Pharmacology|July 23, 2022
Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapyBenjamin Panzer, Patricia P Wadowski, Kurt Huber, et al.
Wiener Medizinische Wochenschrift (1946)|March 16, 2010
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitusSerdar Farhan, Thomas Höchtl, Alexandra Kautzky-Willer, et al.
Journal of Hypertension|May 3, 2016
Awareness, treatment, and control of hypertension in Austria: a multicentre cross-sectional studyMiklos Rohla, Heinz Haberfeld, Maximilian Tscharre, et al.
European Heart Journal|August 24, 2018
Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)Gregory Y H Lip, Jean-Philippe Collet, Michael Haude, et al.
Pageof 76